The Growing Cancer Threat in Africa
Aging

The Growing Cancer Threat in Africa

Cancer mortality is increasing in sub-Saharan Africa, where the needed health care infrastructure is still lacking

Image shows a row of several women wearing colorful scarves on their heads. The camera is looking down the row, and the woman in the foreground is looking at the camera. Two women in the background appear to be talking.
Women sit as they wait for screenings during the breast cancer prevention campaign in Abidjan, Ivory Coast October 12, 2019. REUTERS/Luc Gnago

A deadly disease is expanding fast in sub-Saharan Africa. It already affects hundreds of thousands, and unless governments come together to act soon, millions more will pay the price.

That disease is cancer. While it may be not the latest outbreak of a novel or exotic disease attracting global attention, it is worth remembering, especially on World Cancer Day, that everyday noncommunicable diseases like cancer are the ones that kill the most people. Increasingly, that is true even in the poorer regions of the world.

45 percent

Increase in cancer deaths in sub-Saharan Africa since 2000

In wealthy nations, lower smoking rates, personalized medicine, more screening, better diagnostics, and novel treatments like immunotherapy are reducing cancer rates and improving survival, even among aging populations. Much of that progress, however, is not reaching sub-Saharan Africa. Cancer deaths in sub-Saharan Africa increased 45 percent since 2000, and it now kills more than a half a million people each year. The rise of cancer in sub-Saharan Africa has hit women especially hard. Breast cancer deaths in the region have increased 70 percent since 2000, and it combined with cervical cancer now cause one out of every five cancer deaths in sub-Saharan Africa. In contrast, breast cancer mortality rates have fallen in high-income countries. Cervical cancer, which is completely preventable with HPV vaccine, is increasing becoming a health threat only experienced by poor women in poor nations.

The phot shows a corner of a crowded ward with several women pictured in the frame.
Rukia Kondogoza (right), shares a bed in a crowded hospital ward in Dar es Salaam, Tanzania on Nov 11, 2009 while undergoing treatment for cervical cancer—a major cause of death in sub-Saharan Africa. REUTERS/Katrina Manson

Population growth and aging are fueling a rise in cancers and noncommunicable diseases in sub-Saharan Africa, often in places which are ill-prepared to handle them. Between 2000 and 2020, the number of people between the ages of twenty-five and sixty-four in sub-Saharan Africa grew more 84 percent. As a result, sub-Saharan Africa gained 177 million more adults in that age range in just two decades.

Such dramatic demographic changes are accelerating a shift away from the infectious and nutritional diseases that mostly affect children toward cancer and the other noncommunicable diseases that mostly afflict adults. Treating cancer requires more. It takes more health infrastructure, more clinics, more labs, more hospitals, more X-ray machines and MRIs, and more skilled workers to make accurate diagnoses and perform radiotherapy, chemotherapy and surgery.

‘many countries will not be able to keep up with the pace and scale of the health changes in their populations’

Such infrastructure is expensive, far beyond the health budgets of countries in the region. Between 2000 and 2015, government health spending in sub-Saharan Africa nations grew by more than 4 percent each year. It remains, however, low by global standards. All forty-eight governments in sub-Saharan Africa together spent less on health in 2014 ($67 billion) than the government of Australia ($68 billion). At that rate of spending, many countries will not be able to keep up with the pace and scale of the health changes in their populations. For example, the government of Ethiopia currently spend $17 per person, but is undergoing a dramatic increase in the share of its overall health burden that is associated with cancer and other noncommunicable diseases, from 17 percent in 1990 to a projected 67 percent in 2040.

Image shows a row of several women wearing colorful clothes.
Women sit as they prepare for screenings during the breast cancer prevention campaign in Abidjan, Ivory Coast on October 12, 2019. REUTERS/Luc Gnago

International action can help buy African governments the time and provide the data needed to increase domestic health spending and improve their health infrastructure. More support for population based cancer registries can help nations in the region better define their incidence, mortality, and survival rates of different cancers and formulate national and local plans for improving cancer prevention and treatment. International tobacco control efforts remain woefully underfunded and African nations need help in fighting the multinational cigarette companies that are increasingly targeting the growing young adult populations in the region. Increased investment might also help lower HPV vaccine delivery costs and expand breast cancer screening and diagnosis.

The world’s attention is rightly focused on the threats that outbreaks of emerging infectious disease pose to lives and economies globally. However, we mustn’t let concern for the woeful toll that may be imposed by those dangerous diseases obscure the terrible human and economic cost already imposed by everyday diseases like cancer, increasingly in the poorer regions of the world.

Thomas J. Bollyky is director of the global health program and senior fellow for global health, economics, and development at the Council on Foreign Relations.

Most Popular

Related

Vaccine Hesitancy, an Escalating Danger in Africa

Called one of the ten main threats to global health by WHO, vaccine hesitancy is pervasive, misinformed, and contagious

Dr. Tom Frieden on the Politics of Epidemics

Health protection can fight disease, reduce economic losses, and save lives

Twenty-First Century Epidemic Responses

An interview with Jeremy Farrar, Director of the Wellcome Trust

Mass Drug Administration of Azithromycin: Promise or Peril?

Mass drug administration of azithromycin saves children’s lives—is that enough to justify risk of antibiotic resistance?